Kenneth LaMontagne

Kenneth LaMontagne

Company: Zelluna Immunotherapy

Job title: CBO


A New Paradigm: TCR-NK Cells for Treatment of Solid Tumors 3:30 pm

• Discovery and engineering of TCRs • Advantages of NK cells • How to address the heterogeneity of solid tumorsRead more

day: Conference Day Two

Panel: Unveiling Distinctions: Evaluating TCR-T Cell Therapies, CAR-T, TCR Bispecifics, & Antibody Mimetics for Tailored Therapeutic Advancements 3:00 pm

Quantifying Effectiveness: Comparing the relative affinities, potencies, and safety profiles of T-cell therapies, CAR-T, TCR bispecifics and antibody mimetics to discern their unique therapeutic characteristics Strategic Suitability: Assessing the optimal indications and patient populations where each TCR modality excels Beyond the Horizon: Exploring potential future modalities in the TCR therapy landscape, envisioning the untapped possibilities…Read more


© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.